Cargando…

Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)

Fear of cancer recurrence (FCR) is a pervasive concern for people living with cancer. The rapidly expanding FCR literature has been weakened somewhat by use of miscellaneous FCR measures of varying quality. The Fear of Cancer Recurrence Inventory (FCRI) has been widely used in observational and inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Allan Ben, Costa, Daniel, Galica, Jacqueline, Lebel, Sophie, Tauber, Nina, van Helmondt, Sanne Jasperine, Zachariae, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762428/
https://www.ncbi.nlm.nih.gov/pubmed/33376421
http://dx.doi.org/10.2147/PRBM.S231577
_version_ 1783627803377270784
author Smith, Allan Ben
Costa, Daniel
Galica, Jacqueline
Lebel, Sophie
Tauber, Nina
van Helmondt, Sanne Jasperine
Zachariae, Robert
author_facet Smith, Allan Ben
Costa, Daniel
Galica, Jacqueline
Lebel, Sophie
Tauber, Nina
van Helmondt, Sanne Jasperine
Zachariae, Robert
author_sort Smith, Allan Ben
collection PubMed
description Fear of cancer recurrence (FCR) is a pervasive concern for people living with cancer. The rapidly expanding FCR literature has been weakened somewhat by use of miscellaneous FCR measures of varying quality. The Fear of Cancer Recurrence Inventory (FCRI) has been widely used in observational and intervention studies and the FCRI severity subscale, also known as the FCRI-Short Form (FCRI-SF), is often used to identify potential cases of clinically significant FCR. Given the FCRI’s increasing use in research and clinical practice, we aimed to provide an overview, critique, and suggested improvements of the FCRI. Studies citing the original FCRI validation paper were identified and synthesised using narrative and meta-analytic methods. The 42-item FCRI has demonstrated a reasonably robust 7-factor structure across evaluations in multiple languages, although certain subscales (eg, Coping) demonstrate sub-optimal reliability. Confirmation of the cross-cultural equivalence of several FCRI translations is needed. Meta-analysis of FCRI-SF scores revealed a combined weighted mean score of 15.7/36, a little above the lowest proposed cut-off score (≥13) for clinical FCR. Depending on the FCRI-SF cut-off used, between 30.0% and 53.9% of the cancer population (ie, patients and survivors) appear to experience sub-clinical or clinical FCR. Higher FCRI scores were associated with younger age and female gender, pain/physical symptoms and psychological morbidity, consistent with the FCR literature generally. Issues regarding the application and interpretation of the FCRI remain. Whether the FCRI is well suited to assessing fear of progression as well as recurrence is unclear, the meaningfulness of the FCRI total score is debatable, and the use of the FCRI-SF to screen for clinical FCR is problematic, as items do not reflect established characteristics of clinical FCR. Refinement of the FCRI is needed for it to remain a key FCR assessment tool in future research and clinical practice.
format Online
Article
Text
id pubmed-7762428
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77624282020-12-28 Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) Smith, Allan Ben Costa, Daniel Galica, Jacqueline Lebel, Sophie Tauber, Nina van Helmondt, Sanne Jasperine Zachariae, Robert Psychol Res Behav Manag Review Fear of cancer recurrence (FCR) is a pervasive concern for people living with cancer. The rapidly expanding FCR literature has been weakened somewhat by use of miscellaneous FCR measures of varying quality. The Fear of Cancer Recurrence Inventory (FCRI) has been widely used in observational and intervention studies and the FCRI severity subscale, also known as the FCRI-Short Form (FCRI-SF), is often used to identify potential cases of clinically significant FCR. Given the FCRI’s increasing use in research and clinical practice, we aimed to provide an overview, critique, and suggested improvements of the FCRI. Studies citing the original FCRI validation paper were identified and synthesised using narrative and meta-analytic methods. The 42-item FCRI has demonstrated a reasonably robust 7-factor structure across evaluations in multiple languages, although certain subscales (eg, Coping) demonstrate sub-optimal reliability. Confirmation of the cross-cultural equivalence of several FCRI translations is needed. Meta-analysis of FCRI-SF scores revealed a combined weighted mean score of 15.7/36, a little above the lowest proposed cut-off score (≥13) for clinical FCR. Depending on the FCRI-SF cut-off used, between 30.0% and 53.9% of the cancer population (ie, patients and survivors) appear to experience sub-clinical or clinical FCR. Higher FCRI scores were associated with younger age and female gender, pain/physical symptoms and psychological morbidity, consistent with the FCR literature generally. Issues regarding the application and interpretation of the FCRI remain. Whether the FCRI is well suited to assessing fear of progression as well as recurrence is unclear, the meaningfulness of the FCRI total score is debatable, and the use of the FCRI-SF to screen for clinical FCR is problematic, as items do not reflect established characteristics of clinical FCR. Refinement of the FCRI is needed for it to remain a key FCR assessment tool in future research and clinical practice. Dove 2020-12-21 /pmc/articles/PMC7762428/ /pubmed/33376421 http://dx.doi.org/10.2147/PRBM.S231577 Text en © 2020 Smith et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Smith, Allan Ben
Costa, Daniel
Galica, Jacqueline
Lebel, Sophie
Tauber, Nina
van Helmondt, Sanne Jasperine
Zachariae, Robert
Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)
title Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)
title_full Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)
title_fullStr Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)
title_full_unstemmed Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)
title_short Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)
title_sort spotlight on the fear of cancer recurrence inventory (fcri)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762428/
https://www.ncbi.nlm.nih.gov/pubmed/33376421
http://dx.doi.org/10.2147/PRBM.S231577
work_keys_str_mv AT smithallanben spotlightonthefearofcancerrecurrenceinventoryfcri
AT costadaniel spotlightonthefearofcancerrecurrenceinventoryfcri
AT galicajacqueline spotlightonthefearofcancerrecurrenceinventoryfcri
AT lebelsophie spotlightonthefearofcancerrecurrenceinventoryfcri
AT taubernina spotlightonthefearofcancerrecurrenceinventoryfcri
AT vanhelmondtsannejasperine spotlightonthefearofcancerrecurrenceinventoryfcri
AT zachariaerobert spotlightonthefearofcancerrecurrenceinventoryfcri